Peter Wehrwein

January 22, 2022

Our survey results reflect the reality that American healthcare is inching not galloping to value-based care.

January 20, 2022

Many of the darkest fears about COVID-19 affect on people with HIV have not come to pass. According to a recent review, some evidence suggests that people with HIV may be more likely to develop a severe case of COVID-19, although it isn’t certain. Antiretroviral therapy, especially Truvada, may provide some protection against infection and severity.

January 20, 2022

Almost two-third of the respondents to our survey were in favor of the trend of more state-level regulation of the pharmacy benefit management industry.

January 20, 2022

Cerdá, a member of the Managed Healthcare Executive® editorial advisory board, is part of a new wave of leadership at the Philadelphia-based insurer led by CEO George Deavens.

January 08, 2022

Hospitals in trouble, Moderna booster = 62.5% effectiveness, Supremes hear mandate arguments, get-used-it strategies the new COVID-19 normal, CDC soft pedals testing, and FDA OKs young teen booster

January 07, 2022

The FDA approved Apretude (cabotegravir extended-release injectable suspension) for pre-exposure prophylaxis (PrEP) for HIV in December. Administered as an injection every other month, Apretude gives people at risk of contracting HIV a PrEP alternative to taking daily pills.